ATE501173T1 - Anti-ip-10-antikörper - Google Patents

Anti-ip-10-antikörper

Info

Publication number
ATE501173T1
ATE501173T1 AT04800979T AT04800979T ATE501173T1 AT E501173 T1 ATE501173 T1 AT E501173T1 AT 04800979 T AT04800979 T AT 04800979T AT 04800979 T AT04800979 T AT 04800979T AT E501173 T1 ATE501173 T1 AT E501173T1
Authority
AT
Austria
Prior art keywords
antibodies
present
directed
subject
human
Prior art date
Application number
AT04800979T
Other languages
English (en)
Inventor
Balaji Balasa
Naoya Tsurushita
Nicolas Landolfi
Original Assignee
Abbott Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/014507 external-priority patent/WO2004101511A2/en
Application filed by Abbott Biotherapeutics Corp filed Critical Abbott Biotherapeutics Corp
Priority claimed from PCT/US2004/037600 external-priority patent/WO2005060457A2/en
Application granted granted Critical
Publication of ATE501173T1 publication Critical patent/ATE501173T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/30—Hydrogen technology
    • Y02E60/32—Hydrogen storage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04800979T 2003-12-04 2004-11-10 Anti-ip-10-antikörper ATE501173T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52788203P 2003-12-04 2003-12-04
PCT/US2004/014507 WO2004101511A2 (en) 2003-05-09 2004-05-07 Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases
PCT/US2004/037600 WO2005060457A2 (en) 2003-12-04 2004-11-10 Treatment of inflammatory bowel diseases with anti-ip-10 antibodies

Publications (1)

Publication Number Publication Date
ATE501173T1 true ATE501173T1 (de) 2011-03-15

Family

ID=43646212

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04800979T ATE501173T1 (de) 2003-12-04 2004-11-10 Anti-ip-10-antikörper

Country Status (3)

Country Link
US (1) US7935793B2 (de)
AT (1) ATE501173T1 (de)
DE (1) DE602004031772D1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101333449B1 (ko) 2003-12-10 2013-11-26 메다렉스, 엘.엘.시. Ｉｐ―１０ 항체 및 그의 용도
JP5385159B2 (ja) * 2007-02-28 2014-01-08 ノビミューン エスアー ヒト抗ｉｐ−１０抗体およびその使用
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US20120321687A1 (en) * 2010-02-19 2012-12-20 University Of Virginia Patent Foundation Compositions and methods for using and identifying antimicrobial agents
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
US8790649B2 (en) 2010-10-29 2014-07-29 Immunogen, Inc. EGFR-binding molecules and immunoconjugates thereof
JP2014516944A (ja) 2011-04-29 2014-07-17 ブリストル−マイヤーズ スクイブ カンパニー Ｉｐ１０抗体の用量漸増計画
KR20140105765A (ko) 2011-11-21 2014-09-02 이뮤노젠 아이엔씨 EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
KR101452865B1 (ko) * 2012-09-17 2014-10-21 서울대학교산학협력단 신규한 ｉｐ－１０ 에피토프 및 이에 대한 항체
CA2989993A1 (en) * 2015-09-08 2017-03-16 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
EP3383903A1 (de) 2015-11-30 2018-10-10 Bristol-Myers Squibb Company Humane ip-10-antikörper und deren verwendung
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (de) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Behandlung einer erkrankung des gastrointestinaltraktes mit einem chemokin/chemokin-rezeptor-inhibitor
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN111339181B (zh) * 2020-02-10 2021-08-06 腾讯科技（深圳）有限公司 区块存储方法、装置、节点设备及存储介质
CN114656561B (zh) * 2022-03-05 2023-06-09 南京鼓楼医院 一种抗ip-10单克隆抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3246079A1 (de) 1982-12-13 1984-06-14 Umbach, Albert, 3436 Hessisch Lichtenau Schleifgeraet, insbesondere zum schleifen von zaehnen von kettensaegen
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
IT1181800B (it) 1984-12-19 1987-09-30 Fercad Spa Affilatore a mola rotante particolarmente per seghe a catena per tronchi d'albero
US7297478B1 (en) * 2000-09-22 2007-11-20 Large Scale Biology Corporation Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules

Also Published As

Publication number Publication date
US7935793B2 (en) 2011-05-03
US20080063646A1 (en) 2008-03-13
DE602004031772D1 (de) 2011-04-21

Similar Documents

Publication Publication Date Title
ATE501173T1 (de) Anti-ip-10-antikörper
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
WO2004070011A3 (en) HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
LTC2041177I2 (lt) Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių
ATE549358T1 (de) Neuer anti-plgf-antikörper
BRPI0617485B8 (pt) anticorpo anti-il-13 humano isolado, composição farmacêutica e uso do referido anticorpo
NO20074867L (no) Antistoffer mot CCR5 og anvendelser derav
NZ599683A (en) Anti-ilt7 antibody
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
PE20110801A1 (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f
EA200870050A1 (ru) Анти-il-17-антитела
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
CY1117702T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ικανες να δεσμευονται με θυμικη στρωματικη λεμφοποιητινη
DK1425389T3 (da) Interleukin-15-(IL-15)-specifikke humane antistoffer
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
WO2005026209A3 (en) Monoclonal antibodies against hmgb1
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
ATE502052T1 (de) Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)
MX2009009194A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
DK1802658T3 (da) Kimære og humaniserede monoklonale antistoffer mod interleukin-13
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
JP2009525758A5 (de)
PE20061323A1 (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
NZ712762A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties